Danish Pharmacovigilance Update, May 2011

01 June 2011

In this issue of Danish Pharmacovigilance Update:

  • Risk of renal failure and proteinuria to be added to the summary of product characteristics of Afinitor® (everolimus), which is used for treatment of advanced renal cell carcinoma
  • New warnings for Vectibix® (panitumumab) for treatment of metastatic colorectal carcinoma
  • New warning for Tasigna® (nilotinib) for treatment of chronic myeloid leukaemia
  • Tysabri® for treatment of multiple sclerosis and risk of progressive multifocal leukoencephalopathy (PML)
  • Bricanyl® turbohaler, 200 dose inhaler to be replaced by the 100 dose inhaler due to risk of delivery of excess dose
  • Octagam® to be marketed again
  • Status on adverse reaction reports regarding contraceptive pills
  • New study on the risk of venous thromboembolism from the use of Yasmin®
  • The Danish Medicines Agency’s annual pharmacovigilance report 2010

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.